XXXX profiles of lipopeptides from Bacillus mojavensis A21 and evaluation of their in vitro anticoagulant activity.

@entity137 @entity19 @entity3929 @entity7102 @entity35 @entity165
The aim of the present study was to evaluate the acute and sub-chronic @entity137 of lipopeptides mixture produced by Bacillus mojavensis A21 as well as their in vitro anticoagulant activity. A21 lipopeptides was given to @entity19 at single dose from 75 mg to 1000 mg/kg body weight (bw). The median lethal dose (LD50) of A21 lipopeptides was about 550 mg/kg bw. Sub-chronic @entity137 study for 28 days was done by daily oral administration of A21 lipopeptides at doses of 40 and 400 mg/kg bw in @entity35 . Results showed that A21 lipopeptides did not cause any change in body weights and they did not produce any marked alterations in the hematological blood parameters including hematocrit concentration, hemoglobin level, white and red cells count. However, the platelets level decreased significantly compared to control value. Moreover, no significant differences in the serum biochemical characteristics were observed for @entity35 treated by the lowest dose. In contrast, a little enhancement of @entity3929 -aminotransferase (ALT) activity and decrease in total @entity165 were observed with the highest dose. A21 lipopeptides were also found to cause a prolongation of the @entity7102 time (TT), the prothrombin time (PT) and the activated partial thromboplastin time (APTT). Overall, A21 lipopeptides may be very promising compounds for therapeutic purposes.
